Global Computational Biology Market : Industry Analysis and Forecast (2019-2027) –byServices, Application, End Use, and Region.

Global Computational Biology Market was valued at US$ 2.5 Bn in 2019 and is expected to reach US$10.7Bn by 2027, at a CAGR of 19.93% during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology:-Request Free Sample Report

Global Computational Biology Market Dynamics:

The global computational biology market has witnessed significant growth in recent years because of its assistance in the field of biotechnology and medicine. Combing biology and computers, computational biology helps in drug breakthroughs and consequent development during the several stages of clinical trials. The wide use of computational biology in biotechnology and pharmaceuticals driving the market. Lack of innovative drugs and increasing drug failures in later stages of development had taken its toll on the pharmaceutical industry, amounting to huge financial losses. However, adopting computational biology above a period of time has led to not just minimized clinical stage expenditure but also decreased the frequency of drug failures. This has mainly driven the computational biology market. Additionally, enhanced government funding and industrial support, as well as improved computational tools have driven the growth of the industry. The use of computational biology in modelling and simulation of pediatrics drug development is expected to open various doors for future expansion. Cellular and biological simulation segment is expected to continue leading with over 34.0% market share by 2027. Computational cell modelling and biological simulation aid decipher the biological and physiological functions of cells. Increased unmet medical desires and burgeoning demand for personalized medicine are expected to shape the future growth of the application segment. Commercial led the end use segment in 2019, attributed to the rise in the bioinformatics research, drug designing, and usage in personalized medicine. Such as, in August 2018, the European Union and India’s Department of Biotechnology (DBT) announced the fund of US$ 17.2 Mn towards research and innovation for the development of next-generation influenza virus to protect individuals worldwide.

Global Computational Biology Market Regional Insights:

North America is expected to contribute to the largest market share in the computational biology market in the coming years, because of increasing investments made in R&D activities for the discovery as well as the development of novel drugs. Also, the Asia Pacific is anticipated to witness steady growth during the forecast period, owing to increasing clinical trials in the region. In Feb 2019, StemoniX Inc., the USA based provider of product and services for drug discovery and development, received funding of US$ 14.40 Mn from a group of investors. Brightstone Venture Capital was the major financer and was later combined by Crescent Ridge Partners, Alumni Ventures Group, and Mayo Clinic. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Computational Biology Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Computational Biology Market.

Global Computational Biology Market, Key Highlights:

• Global Computational Biology Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Computational Biology Market • Global Computational Biology Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Global Computational Biology Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Global Computational Biology Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Computational Biology Market are also profiled. The report has considered the base year of 2019 and past four years trend. 2020 figures are at actuals, however due to different dynamics of year 2020, market forecast is not only dependent upon 2020, but on the basis of 2016-2020.

Scope of the Global Computational Biology Market: Inquire before buying

Global Computational Biology Market, by Application

• Cellular & Biological Simulation o Computational Genomics  Databases  Infrastructure/Hardware  Software & Services o Computational Proteomics o Pharmacogenomics o Others (Transcriptomics/ Metabolomics) • Drug Discovery & Disease Modelling o Target Identification o Target Validation o Lead Discovery o Lead Optimization • Preclinical Drug Development o Pharmacokinetic o Pharmacodynamics • Clinical Trials o Phase I o Phase II o Phase III • Human Body Simulation Software

Global Computational Biology Market, by Services

• In-house • Contract

Global Computational Biology Market, by End Use

• Academics • Industry • Commercial

Global Computational Biology Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • Latin America

Global Computational Biology Market Key Player

• DassaultSystèmes SE • Certara • Chemical Computing Group ULC • Compugen Ltd • Rosa & Co. LLC • Genedata AG • Insilico Biotechnology AG • Leadscope Inc. • Nimbus Discovery LLC • Strand Life Sciences • Schrodinger • Simulation Plus Inc. • Accelrys • Entelos • RhenoviaPharma Sa • StemoniXInc • Computational Genomics Laboratory • Elucidata • DNAnexus • Simons Foundation

Table of Content

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary : Global Computational Biology Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends in Global Computational Biology Market 5. Supply Side and Demand Side Indicators 6. Global Computational Biology Market Analysis and Forecast 6.1. Global Computational Biology Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Computational Biology Market Analysis and Forecast, by Services 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Computational Biology Market Value Share Analysis, by Services 7.4. Global Computational Biology Market Size (US$ Bn) Forecast, by Services 7.5. Global Computational Biology Market Analysis, by Services 7.6. Global Computational Biology Market Attractiveness Analysis, by Services 8. Global Computational Biology Market Analysis and Forecast, by Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Computational Biology Market Value Share Analysis, by Application 8.4. Global Computational Biology Market Size (US$ Bn) Forecast, by Application 8.5. Global Computational Biology Market Analysis, by Application 8.6. Global Computational Biology Market Attractiveness Analysis, by Application 9. Global Computational Biology Market Analysis and Forecast, by End Use 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Computational Biology Market Value Share Analysis, by End Use 9.4. Global Computational Biology Market Size (US$ Bn) Forecast, by End Use 9.5. Global Computational Biology Market Analysis, by End Use 9.6. Global Computational Biology Market Attractiveness Analysis, by End Use 10. Global Computational Biology Market Analysis, by Region 10.1. Global Computational Biology Market Value Share Analysis, by Region 10.2. Global Computational Biology Market Size (US$ Bn) Forecast, by Region 10.3. Global Computational Biology Market Attractiveness Analysis, by Region 11. North America Computational Biology Market Analysis 11.1. Key Findings 11.2. North America Computational Biology Market Overview 11.3. North America Computational Biology Market Value Share Analysis, by Services 11.4. North America Computational Biology Market Forecast, by Services 11.4.1. In-house 11.4.2. Contract 11.5. North America Computational Biology Market Value Share Analysis, by Application 11.6. North America Computational Biology Market Forecast, by Application 11.6.1. Cellular & Biological Simulation 11.6.1.1. Computational Genomics 11.6.1.1.1. Databases 11.6.1.1.2. Infrastructure/Hardware 11.6.1.1.3. Software & Services 11.6.1.2. Computational Proteomics 11.6.1.3. Pharmacogenomics 11.6.1.4. Others (Transcriptomics/ Metabolomics) 11.6.2. Drug Discovery & Disease Modelling 11.6.2.1. Target Identification 11.6.2.2. Target Validation 11.6.2.3. Lead Discovery 11.6.2.4. Lead Optimization 11.6.3. Preclinical Drug Development 11.6.3.1. Pharmacokinetic 11.6.3.2. Pharmacodynamics 11.6.4. Clinical Trials 11.6.4.1. Phase I 11.6.4.2. Phase II 11.6.4.3. Phase III 11.6.5. Human Body Simulation Software 11.7. North America Computational Biology Market Value Share Analysis, by End Use 11.8. North America Computational Biology Market Forecast, by End Use 11.8.1. Academics 11.8.2. Industry 11.8.3. Commercial 11.9. North America Computational Biology Market Value Share Analysis, by Country 11.10. North America Computational Biology Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Computational Biology Market Analysis, by Country 11.12. U.S. Computational Biology Market Forecast, by Services 11.12.1. In-house 11.12.2. Contract 11.13. U.S. Computational Biology Market Forecast, by Application 11.13.1. Cellular & Biological Simulation 11.13.1.1. Computational Genomics 11.13.1.1.1. Databases 11.13.1.1.2. Infrastructure/Hardware 11.13.1.1.3. Software & Services 11.13.1.2. Computational Proteomics 11.13.1.3. Pharmacogenomics 11.13.1.4. Others (Transcriptomics/ Metabolomics) 11.13.2. Drug Discovery & Disease Modelling 11.13.2.1. Target Identification 11.13.2.2. Target Validation 11.13.2.3. Lead Discovery 11.13.2.4. Lead Optimization 11.13.3. Preclinical Drug Development 11.13.3.1. Pharmacokinetic 11.13.3.2. Pharmacodynamics 11.13.4. Clinical Trials 11.13.4.1. Phase I 11.13.4.2. Phase II 11.13.4.3. Phase III 11.13.5. Human Body Simulation Software 11.14. U.S. Computational Biology Market Forecast, by End Use 11.14.1. Academics 11.14.2. Industry 11.14.3. Commercial 11.15. Canada Computational Biology Market Forecast, by Services 11.15.1. In-house 11.15.2. Contract 11.16. Canada Computational Biology Market Forecast, by Application 11.16.1. Cellular & Biological Simulation 11.16.1.1. Computational Genomics 11.16.1.1.1. Databases 11.16.1.1.2. Infrastructure/Hardware 11.16.1.1.3. Software & Services 11.16.1.2. Computational Proteomics 11.16.1.3. Pharmacogenomics 11.16.1.4. Others (Transcriptomics/ Metabolomics) 11.16.2. Drug Discovery & Disease Modelling 11.16.2.1. Target Identification 11.16.2.2. Target Validation 11.16.2.3. Lead Discovery 11.16.2.4. Lead Optimization 11.16.3. Preclinical Drug Development 11.16.3.1. Pharmacokinetic 11.16.3.2. Pharmacodynamics 11.16.4. Clinical Trials 11.16.4.1. Phase I 11.16.4.2. Phase II 11.16.4.3. Phase III 11.16.5. Human Body Simulation Software 11.17. Canada Computational Biology Market Forecast, by End Use 11.17.1. Academics 11.17.2. Industry 11.17.3. Commercial 11.18. North America Computational Biology Market Attractiveness Analysis 11.18.1. By Services 11.18.2. By Application 11.18.3. By End Use 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Computational Biology Market Analysis 12.1. Key Findings 12.2. Europe Computational Biology Market Overview 12.3. Europe Computational Biology Market Value Share Analysis, by Services 12.4. Europe Computational Biology Market Forecast, by Services 12.4.1. In-house 12.4.2. Contract 12.5. Europe Computational Biology Market Value Share Analysis, by Application 12.6. Europe Computational Biology Market Forecast, by Application 12.6.1. Cellular & Biological Simulation 12.6.1.1. Computational Genomics 12.6.1.1.1. Databases 12.6.1.1.2. Infrastructure/Hardware 12.6.1.1.3. Software & Services 12.6.1.2. Computational Proteomics 12.6.1.3. Pharmacogenomics 12.6.1.4. Others (Transcriptomics/ Metabolomics) 12.6.2. Drug Discovery & Disease Modelling 12.6.2.1. Target Identification 12.6.2.2. Target Validation 12.6.2.3. Lead Discovery 12.6.2.4. Lead Optimization 12.6.3. Preclinical Drug Development 12.6.3.1. Pharmacokinetic 12.6.3.2. Pharmacodynamics 12.6.4. Clinical Trials 12.6.4.1. Phase I 12.6.4.2. Phase II 12.6.4.3. Phase III 12.6.5. Human Body Simulation Software 12.7. Europe Computational Biology Market Value Share Analysis, by End Use 12.8. Europe Computational Biology Market Forecast, by End Use 12.8.1. Academics 12.8.2. Industry 12.8.3. Commercial 12.9. Europe Computational Biology Market Value Share Analysis, by Country 12.10. Europe Computational Biology Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Computational Biology Market Analysis, by Country 12.12. Germany Computational Biology Market Forecast, by Services 12.12.1. In-house 12.12.2. Contract 12.13. Germany Computational Biology Market Forecast, by Application 12.13.1. Cellular & Biological Simulation 12.13.1.1. Computational Genomics 12.13.1.1.1. Databases 12.13.1.1.2. Infrastructure/Hardware 12.13.1.1.3. Software & Services 12.13.1.2. Computational Proteomics 12.13.1.3. Pharmacogenomics 12.13.1.4. Others (Transcriptomics/ Metabolomics) 12.13.2. Drug Discovery & Disease Modelling 12.13.2.1. Target Identification 12.13.2.2. Target Validation 12.13.2.3. Lead Discovery 12.13.2.4. Lead Optimization 12.13.3. Preclinical Drug Development 12.13.3.1. Pharmacokinetic 12.13.3.2. Pharmacodynamics 12.13.4. Clinical Trials 12.13.4.1. Phase I 12.13.4.2. Phase II 12.13.4.3. Phase III 12.13.5. Human Body Simulation Software 12.14. Germany Computational Biology Market Forecast, by End Use 12.14.1. Academics 12.14.2. Industry 12.14.3. Commercial 12.15. U.K. Computational Biology Market Forecast, by Services 12.15.1. In-house 12.15.2. Contract 12.16. U.K. Computational Biology Market Forecast, by Application 12.16.1. Cellular & Biological Simulation 12.16.1.1. Computational Genomics 12.16.1.1.1. Databases 12.16.1.1.2. Infrastructure/Hardware 12.16.1.1.3. Software & Services 12.16.1.2. Computational Proteomics 12.16.1.3. Pharmacogenomics 12.16.1.4. Others (Transcriptomics/ Metabolomics) 12.16.2. Drug Discovery & Disease Modelling 12.16.2.1. Target Identification 12.16.2.2. Target Validation 12.16.2.3. Lead Discovery 12.16.2.4. Lead Optimization 12.16.3. Preclinical Drug Development 12.16.3.1. Pharmacokinetic 12.16.3.2. Pharmacodynamics 12.16.4. Clinical Trials 12.16.4.1. Phase I 12.16.4.2. Phase II 12.16.4.3. Phase III 12.16.5. Human Body Simulation Software 12.17. U.K. Computational Biology Market Forecast, by End Use 12.17.1. Academics 12.17.2. Industry 12.17.3. Commercial 12.18. France Computational Biology Market Forecast, by Services 12.18.1. In-house 12.18.2. Contract 12.19. France Computational Biology Market Forecast, by Application 12.19.1. Cellular & Biological Simulation 12.19.1.1. Computational Genomics 12.19.1.1.1. Databases 12.19.1.1.2. Infrastructure/Hardware 12.19.1.1.3. Software & Services 12.19.1.2. Computational Proteomics 12.19.1.3. Pharmacogenomics 12.19.1.4. Others (Transcriptomics/ Metabolomics) 12.19.2. Drug Discovery & Disease Modelling 12.19.2.1. Target Identification 12.19.2.2. Target Validation 12.19.2.3. Lead Discovery 12.19.2.4. Lead Optimization 12.19.3. Preclinical Drug Development 12.19.3.1. Pharmacokinetic 12.19.3.2. Pharmacodynamics 12.19.4. Clinical Trials 12.19.4.1. Phase I 12.19.4.2. Phase II 12.19.4.3. Phase III 12.19.5. Human Body Simulation Software 12.20. France Computational Biology Market Forecast, by End Use 12.20.1. Academics 12.20.2. Industry 12.20.3. Commercial 12.21. Italy Computational Biology Market Forecast, by Services 12.21.1. In-house 12.21.2. Contract 12.22. Italy Computational Biology Market Forecast, by Application 12.22.1. Cellular & Biological Simulation 12.22.1.1. Computational Genomics 12.22.1.1.1. Databases 12.22.1.1.2. Infrastructure/Hardware 12.22.1.1.3. Software & Services 12.22.1.2. Computational Proteomics 12.22.1.3. Pharmacogenomics 12.22.1.4. Others (Transcriptomics/ Metabolomics) 12.22.2. Drug Discovery & Disease Modelling 12.22.2.1. Target Identification 12.22.2.2. Target Validation 12.22.2.3. Lead Discovery 12.22.2.4. Lead Optimization 12.22.3. Preclinical Drug Development 12.22.3.1. Pharmacokinetic 12.22.3.2. Pharmacodynamics 12.22.4. Clinical Trials 12.22.4.1. Phase I 12.22.4.2. Phase II 12.22.4.3. Phase III 12.22.5. Human Body Simulation Software 12.23. Italy Computational Biology Market Forecast, by End Use 12.23.1. Academics 12.23.2. Industry 12.23.3. Commercial 12.24. Spain Computational Biology Market Forecast, by Services 12.24.1. In-house 12.24.2. Contract 12.25. Spain Computational Biology Market Forecast, by Application 12.25.1. Cellular & Biological Simulation 12.25.1.1. Computational Genomics 12.25.1.1.1. Databases 12.25.1.1.2. Infrastructure/Hardware 12.25.1.1.3. Software & Services 12.25.1.2. Computational Proteomics 12.25.1.3. Pharmacogenomics 12.25.1.4. Others (Transcriptomics/ Metabolomics) 12.25.2. Drug Discovery & Disease Modelling 12.25.2.1. Target Identification 12.25.2.2. Target Validation 12.25.2.3. Lead Discovery 12.25.2.4. Lead Optimization 12.25.3. Preclinical Drug Development 12.25.3.1. Pharmacokinetic 12.25.3.2. Pharmacodynamics 12.25.4. Clinical Trials 12.25.4.1. Phase I 12.25.4.2. Phase II 12.25.4.3. Phase III 12.25.5. Human Body Simulation Software 12.26. Spain Computational Biology Market Forecast, by End Use 12.26.1. Academics 12.26.2. Industry 12.26.3. Commercial 12.27. Rest of Europe Computational Biology Market Forecast, by Services 12.27.1. In-house 12.27.2. Contract 12.28. Rest of Europe Computational Biology Market Forecast, by Application 12.28.1. Cellular & Biological Simulation 12.28.1.1. Computational Genomics 12.28.1.1.1. Databases 12.28.1.1.2. Infrastructure/Hardware 12.28.1.1.3. Software & Services 12.28.1.2. Computational Proteomics 12.28.1.3. Pharmacogenomics 12.28.1.4. Others (Transcriptomics/ Metabolomics) 12.28.2. Drug Discovery & Disease Modelling 12.28.2.1. Target Identification 12.28.2.2. Target Validation 12.28.2.3. Lead Discovery 12.28.2.4. Lead Optimization 12.28.3. Preclinical Drug Development 12.28.3.1. Pharmacokinetic 12.28.3.2. Pharmacodynamics 12.28.4. Clinical Trials 12.28.4.1. Phase I 12.28.4.2. Phase II 12.28.4.3. Phase III 12.28.5. Human Body Simulation Software 12.29. Rest Of Europe Computational Biology Market Forecast, by End Use 12.29.1. Academics 12.29.2. Industry 12.29.3. Commercial 12.30. Europe Computational Biology Market Attractiveness Analysis 12.30.1. By Services 12.30.2. By Application 12.30.3. By End Use 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Computational Biology Market Analysis 13.1. Key Findings 13.2. Asia Pacific Computational Biology Market Overview 13.3. Asia Pacific Computational Biology Market Value Share Analysis, by Services 13.4. Asia Pacific Computational Biology Market Forecast, by Services 13.4.1. In-house 13.4.2. Contract 13.5. Asia Pacific Computational Biology Market Value Share Analysis, by Application 13.6. Asia Pacific Computational Biology Market Forecast, by Application 13.6.1. Cellular & Biological Simulation 13.6.1.1. Computational Genomics 13.6.1.1.1. Databases 13.6.1.1.2. Infrastructure/Hardware 13.6.1.1.3. Software & Services 13.6.1.2. Computational Proteomics 13.6.1.3. Pharmacogenomics 13.6.1.4. Others (Transcriptomics/ Metabolomics) 13.6.2. Drug Discovery & Disease Modelling 13.6.2.1. Target Identification 13.6.2.2. Target Validation 13.6.2.3. Lead Discovery 13.6.2.4. Lead Optimization 13.6.3. Preclinical Drug Development 13.6.3.1. Pharmacokinetic 13.6.3.2. Pharmacodynamics 13.6.4. Clinical Trials 13.6.4.1. Phase I 13.6.4.2. Phase II 13.6.4.3. Phase III 13.6.5. Human Body Simulation Software 13.7. Asia Pacific Computational Biology Market Value Share Analysis, by End Use 13.8. Asia Pacific Computational Biology Market Forecast, by End Use 13.8.1. Academics 13.8.2. Industry 13.8.3. Commercial 13.9. Asia Pacific Computational Biology Market Value Share Analysis, by Country 13.10. Asia Pacific Computational Biology Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Computational Biology Market Analysis, by Country 13.12. China Computational Biology Market Forecast, by Services 13.12.1. In-house 13.12.2. Contract 13.13. China Computational Biology Market Forecast, by Application 13.13.1. Cellular & Biological Simulation 13.13.1.1. Computational Genomics 13.13.1.1.1. Databases 13.13.1.1.2. Infrastructure/Hardware 13.13.1.1.3. Software & Services 13.13.1.2. Computational Proteomics 13.13.1.3. Pharmacogenomics 13.13.1.4. Others (Transcriptomics/ Metabolomics) 13.13.2. Drug Discovery & Disease Modelling 13.13.2.1. Target Identification 13.13.2.2. Target Validation 13.13.2.3. Lead Discovery 13.13.2.4. Lead Optimization 13.13.3. Preclinical Drug Development 13.13.3.1. Pharmacokinetic 13.13.3.2. Pharmacodynamics 13.13.4. Clinical Trials 13.13.4.1. Phase I 13.13.4.2. Phase II 13.13.4.3. Phase III 13.13.5. Human Body Simulation Software 13.14. China Computational Biology Market Forecast, by End Use 13.14.1. Academics 13.14.2. Industry 13.14.3. Commercial 13.15. India Computational Biology Market Forecast, by Services 13.15.1. In-house 13.15.2. Contract 13.16. India Computational Biology Market Forecast, by Application 13.16.1. Cellular & Biological Simulation 13.16.1.1. Computational Genomics 13.16.1.1.1. Databases 13.16.1.1.2. Infrastructure/Hardware 13.16.1.1.3. Software & Services 13.16.1.2. Computational Proteomics 13.16.1.3. Pharmacogenomics 13.16.1.4. Others (Transcriptomics/ Metabolomics) 13.16.2. Drug Discovery & Disease Modelling 13.16.2.1. Target Identification 13.16.2.2. Target Validation 13.16.2.3. Lead Discovery 13.16.2.4. Lead Optimization 13.16.3. Preclinical Drug Development 13.16.3.1. Pharmacokinetic 13.16.3.2. Pharmacodynamics 13.16.4. Clinical Trials 13.16.4.1. Phase I 13.16.4.2. Phase II 13.16.4.3. Phase III 13.16.5. Human Body Simulation Software 13.17. India Computational Biology Market Forecast, by End Use 13.17.1. Academics 13.17.2. Industry 13.17.3. Commercial 13.18. Japan Computational Biology Market Forecast, by Services 13.18.1. In-house 13.18.2. Contract 13.19. Japan Computational Biology Market Forecast, by Application 13.19.1. Cellular & Biological Simulation 13.19.1.1. Computational Genomics 13.19.1.1.1. Databases 13.19.1.1.2. Infrastructure/Hardware 13.19.1.1.3. Software & Services 13.19.1.2. Computational Proteomics 13.19.1.3. Pharmacogenomics 13.19.1.4. Others (Transcriptomics/ Metabolomics) 13.19.2. Drug Discovery & Disease Modelling 13.19.2.1. Target Identification 13.19.2.2. Target Validation 13.19.2.3. Lead Discovery 13.19.2.4. Lead Optimization 13.19.3. Preclinical Drug Development 13.19.3.1. Pharmacokinetic 13.19.3.2. Pharmacodynamics 13.19.4. Clinical Trials 13.19.4.1. Phase I 13.19.4.2. Phase II 13.19.4.3. Phase III 13.19.5. Human Body Simulation Software 13.20. Japan Computational Biology Market Forecast, by End Use 13.20.1. Academics 13.20.2. Industry 13.20.3. Commercial 13.21. ASEAN Computational Biology Market Forecast, by Services 13.21.1. In-house 13.21.2. Contract 13.22. ASEAN Computational Biology Market Forecast, by Application 13.22.1. Cellular & Biological Simulation 13.22.1.1. Computational Genomics 13.22.1.1.1. Databases 13.22.1.1.2. Infrastructure/Hardware 13.22.1.1.3. Software & Services 13.22.1.2. Computational Proteomics 13.22.1.3. Pharmacogenomics 13.22.1.4. Others (Transcriptomics/ Metabolomics) 13.22.2. Drug Discovery & Disease Modelling 13.22.2.1. Target Identification 13.22.2.2. Target Validation 13.22.2.3. Lead Discovery 13.22.2.4. Lead Optimization 13.22.3. Preclinical Drug Development 13.22.3.1. Pharmacokinetic 13.22.3.2. Pharmacodynamics 13.22.4. Clinical Trials 13.22.4.1. Phase I 13.22.4.2. Phase II 13.22.4.3. Phase III 13.22.5. Human Body Simulation Software 13.23. ASEAN Computational Biology Market Forecast, by End Use 13.23.1. Academics 13.23.2. Industry 13.23.3. Commercial 13.24. Rest of Asia Pacific Computational Biology Market Forecast, by Services 13.24.1. In-house 13.24.2. Contract 13.25. Rest of Asia Pacific Computational Biology Market Forecast, by Application 13.25.1. Cellular & Biological Simulation 13.25.1.1. Computational Genomics 13.25.1.1.1. Databases 13.25.1.1.2. Infrastructure/Hardware 13.25.1.1.3. Software & Services 13.25.1.2. Computational Proteomics 13.25.1.3. Pharmacogenomics 13.25.1.4. Others (Transcriptomics/ Metabolomics) 13.25.2. Drug Discovery & Disease Modelling 13.25.2.1. Target Identification 13.25.2.2. Target Validation 13.25.2.3. Lead Discovery 13.25.2.4. Lead Optimization 13.25.3. Preclinical Drug Development 13.25.3.1. Pharmacokinetic 13.25.3.2. Pharmacodynamics 13.25.4. Clinical Trials 13.25.4.1. Phase I 13.25.4.2. Phase II 13.25.4.3. Phase III 13.25.5. Human Body Simulation Software 13.26. Rest of Asia Pacific Computational Biology Market Forecast, by End Use 13.26.1. Academics 13.26.2. Industry 13.26.3. Commercial 13.27. Asia Pacific Computational Biology Market Attractiveness Analysis 13.27.1. By Services 13.27.2. By Application 13.27.3. By End Use 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Computational Biology Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Computational Biology Market Overview 14.3. Middle East & Africa Computational Biology Market Value Share Analysis, by Services 14.4. Middle East & Africa Computational Biology Market Forecast, by Services 14.4.1. In-house 14.4.2. Contract 14.5. Middle East & Africa Computational Biology Market Value Share Analysis, by Application 14.6. Middle East & Africa Computational Biology Market Forecast, by Application 14.6.1. Cellular & Biological Simulation 14.6.1.1. Computational Genomics 14.6.1.1.1. Databases 14.6.1.1.2. Infrastructure/Hardware 14.6.1.1.3. Software & Services 14.6.1.2. Computational Proteomics 14.6.1.3. Pharmacogenomics 14.6.1.4. Others (Transcriptomics/ Metabolomics) 14.6.2. Drug Discovery & Disease Modelling 14.6.2.1. Target Identification 14.6.2.2. Target Validation 14.6.2.3. Lead Discovery 14.6.2.4. Lead Optimization 14.6.3. Preclinical Drug Development 14.6.3.1. Pharmacokinetic 14.6.3.2. Pharmacodynamics 14.6.4. Clinical Trials 14.6.4.1. Phase I 14.6.4.2. Phase II 14.6.4.3. Phase III 14.6.5. Human Body Simulation Software 14.7. Middle East & Africa Computational Biology Market Value Share Analysis, by End Use 14.8. Middle East & Africa Computational Biology Market Forecast, by End Use 14.8.1. Academics 14.8.2. Industry 14.8.3. Commercial 14.9. Middle East & Africa Computational Biology Market Value Share Analysis, by Country 14.10. Middle East & Africa Computational Biology Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Computational Biology Market Analysis, by Country 14.12. GCC Computational Biology Market Forecast, by Services 14.12.1. In-house 14.12.2. Contract 14.13. GCC Computational Biology Market Forecast, by Application 14.13.1. Cellular & Biological Simulation 14.13.1.1. Computational Genomics 14.13.1.1.1. Databases 14.13.1.1.2. Infrastructure/Hardware 14.13.1.1.3. Software & Services 14.13.1.2. Computational Proteomics 14.13.1.3. Pharmacogenomics 14.13.1.4. Others (Transcriptomics/ Metabolomics) 14.13.2. Drug Discovery & Disease Modelling 14.13.2.1. Target Identification 14.13.2.2. Target Validation 14.13.2.3. Lead Discovery 14.13.2.4. Lead Optimization 14.13.3. Preclinical Drug Development 14.13.3.1. Pharmacokinetic 14.13.3.2. Pharmacodynamics 14.13.4. Clinical Trials 14.13.4.1. Phase I 14.13.4.2. Phase II 14.13.4.3. Phase III 14.13.5. Human Body Simulation Software 14.14. GCC Computational Biology Market Forecast, by End Use 14.14.1. Academics 14.14.2. Industry 14.14.3. Commercial 14.15. South Africa Computational Biology Market Forecast, by Services 14.15.1. In-house 14.15.2. Contract 14.16. South Africa Computational Biology Market Forecast, by Application 14.16.1. Cellular & Biological Simulation 14.16.1.1. Computational Genomics 14.16.1.1.1. Databases 14.16.1.1.2. Infrastructure/Hardware 14.16.1.1.3. Software & Services 14.16.1.2. Computational Proteomics 14.16.1.3. Pharmacogenomics 14.16.1.4. Others (Transcriptomics/ Metabolomics) 14.16.2. Drug Discovery & Disease Modelling 14.16.2.1. Target Identification 14.16.2.2. Target Validation 14.16.2.3. Lead Discovery 14.16.2.4. Lead Optimization 14.16.3. Preclinical Drug Development 14.16.3.1. Pharmacokinetic 14.16.3.2. Pharmacodynamics 14.16.4. Clinical Trials 14.16.4.1. Phase I 14.16.4.2. Phase II 14.16.4.3. Phase III 14.16.5. Human Body Simulation Software 14.17. South Africa Computational Biology Market Forecast, by End Use 14.17.1. Academics 14.17.2. Industry 14.17.3. Commercial 14.18. Rest of Middle East & Africa Computational Biology Market Forecast, by Services 14.18.1. In-house 14.18.2. Contract 14.19. Rest of Middle East & Africa Computational Biology Market Forecast, by Application 14.19.1. Cellular & Biological Simulation 14.19.1.1. Computational Genomics 14.19.1.1.1. Databases 14.19.1.1.2. Infrastructure/Hardware 14.19.1.1.3. Software & Services 14.19.1.2. Computational Proteomics 14.19.1.3. Pharmacogenomics 14.19.1.4. Others (Transcriptomics/ Metabolomics) 14.19.2. Drug Discovery & Disease Modelling 14.19.2.1. Target Identification 14.19.2.2. Target Validation 14.19.2.3. Lead Discovery 14.19.2.4. Lead Optimization 14.19.3. Preclinical Drug Development 14.19.3.1. Pharmacokinetic 14.19.3.2. Pharmacodynamics 14.19.4. Clinical Trials 14.19.4.1. Phase I 14.19.4.2. Phase II 14.19.4.3. Phase III 14.19.5. Human Body Simulation Software 14.20. Rest of Middle East & Africa Computational Biology Market Forecast, by End Use 14.20.1. Academics 14.20.2. Industry 14.20.3. Commercial 14.21. Middle East & Africa Computational Biology Market Attractiveness Analysis 14.21.1. By Services 14.21.2. By Application 14.21.3. By End Use 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Computational Biology Market Analysis 15.1. Key Findings 15.2. South America Computational Biology Market Overview 15.3. South America Computational Biology Market Value Share Analysis, by Services 15.4. South America Computational Biology Market Forecast, by Services 15.4.1. In-house 15.4.2. Contract 15.5. South America Computational Biology Market Value Share Analysis, by Application 15.6. South America Computational Biology Market Forecast, by Application 15.6.1. Cellular & Biological Simulation 15.6.1.1. Computational Genomics 15.6.1.1.1. Databases 15.6.1.1.2. Infrastructure/Hardware 15.6.1.1.3. Software & Services 15.6.1.2. Computational Proteomics 15.6.1.3. Pharmacogenomics 15.6.1.4. Others (Transcriptomics/ Metabolomics) 15.6.2. Drug Discovery & Disease Modelling 15.6.2.1. Target Identification 15.6.2.2. Target Validation 15.6.2.3. Lead Discovery 15.6.2.4. Lead Optimization 15.6.3. Preclinical Drug Development 15.6.3.1. Pharmacokinetic 15.6.3.2. Pharmacodynamics 15.6.4. Clinical Trials 15.6.4.1. Phase I 15.6.4.2. Phase II 15.6.4.3. Phase III 15.6.5. Human Body Simulation Software 15.7. South America Computational Biology Market Value Share Analysis, by End Use 15.8. South America Computational Biology Market Forecast, by End Use 15.8.1. Academics 15.8.2. Industry 15.8.3. Commercial 15.9. South America Computational Biology Market Value Share Analysis, by Country 15.10. South America Computational Biology Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Computational Biology Market Analysis, by Country 15.12. Brazil Computational Biology Market Forecast, by Services 15.12.1. In-house 15.12.2. Contract 15.13. Brazil Computational Biology Market Forecast, by Application 15.13.1. Cellular & Biological Simulation 15.13.1.1. Computational Genomics 15.13.1.1.1. Databases 15.13.1.1.2. Infrastructure/Hardware 15.13.1.1.3. Software & Services 15.13.1.2. Computational Proteomics 15.13.1.3. Pharmacogenomics 15.13.1.4. Others (Transcriptomics/ Metabolomics) 15.13.2. Drug Discovery & Disease Modelling 15.13.2.1. Target Identification 15.13.2.2. Target Validation 15.13.2.3. Lead Discovery 15.13.2.4. Lead Optimization 15.13.3. Preclinical Drug Development 15.13.3.1. Pharmacokinetic 15.13.3.2. Pharmacodynamics 15.13.4. Clinical Trials 15.13.4.1. Phase I 15.13.4.2. Phase II 15.13.4.3. Phase III 15.13.5. Human Body Simulation Software 15.14. Brazil Computational Biology Market Forecast, by End Use 15.14.1. Academics 15.14.2. Industry 15.14.3. Commercial 15.15. Mexico Computational Biology Market Forecast, by Services 15.15.1. In-house 15.15.2. Contract 15.16. Mexico Computational Biology Market Forecast, by Application 15.16.1. Cellular & Biological Simulation 15.16.1.1. Computational Genomics 15.16.1.1.1. Databases 15.16.1.1.2. Infrastructure/Hardware 15.16.1.1.3. Software & Services 15.16.1.2. Computational Proteomics 15.16.1.3. Pharmacogenomics 15.16.1.4. Others (Transcriptomics/ Metabolomics) 15.16.2. Drug Discovery & Disease Modelling 15.16.2.1. Target Identification 15.16.2.2. Target Validation 15.16.2.3. Lead Discovery 15.16.2.4. Lead Optimization 15.16.3. Preclinical Drug Development 15.16.3.1. Pharmacokinetic 15.16.3.2. Pharmacodynamics 15.16.4. Clinical Trials 15.16.4.1. Phase I 15.16.4.2. Phase II 15.16.4.3. Phase III 15.16.5. Human Body Simulation Software 15.17. Mexico Computational Biology Market Forecast, by End Use 15.17.1. Academics 15.17.2. Industry 15.17.3. Commercial 15.18. Rest of South America Computational Biology Market Forecast, by Services 15.18.1. In-house 15.18.2. Contract 15.19. Rest of South America Computational Biology Market Forecast, by Application 15.19.1. Cellular & Biological Simulation 15.19.1.1. Computational Genomics 15.19.1.1.1. Databases 15.19.1.1.2. Infrastructure/Hardware 15.19.1.1.3. Software & Services 15.19.1.2. Computational Proteomics 15.19.1.3. Pharmacogenomics 15.19.1.4. Others (Transcriptomics/ Metabolomics) 15.19.2. Drug Discovery & Disease Modelling 15.19.2.1. Target Identification 15.19.2.2. Target Validation 15.19.2.3. Lead Discovery 15.19.2.4. Lead Optimization 15.19.3. Preclinical Drug Development 15.19.3.1. Pharmacokinetic 15.19.3.2. Pharmacodynamics 15.19.4. Clinical Trials 15.19.4.1. Phase I 15.19.4.2. Phase II 15.19.4.3. Phase III 15.19.5. Human Body Simulation Software 15.20. Rest of South America Computational Biology Market Forecast, by End Use 15.20.1. Academics 15.20.2. Industry 15.20.3. Commercial 15.21. South America Computational Biology Market Attractiveness Analysis 15.21.1. By Services 15.21.2. By Application 15.21.3. By End Use 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. DassaultSystèmes SE 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Certara 16.3.3. Chemical Computing Group ULC 16.3.4. Compugen Ltd 16.3.5. Rosa & Co. LLC 16.3.6. Genedata AG 16.3.7. Insilico Biotechnology AG 16.3.8. Leadscope Inc. 16.3.9. Nimbus Discovery LLC 16.3.10. Strand Life Sciences 16.3.11. Schrodinger 16.3.12. Simulation Plus Inc. 16.3.13. Accelrys 16.3.14. Entelos 16.3.15. RhenoviaPharma SA 16.3.16. StemoniXInc 16.3.17. Computational Genomics Laboratory 16.3.18. Elucidata 16.3.19. DNAnexus 16.3.20. Simons Foundation 17. Primary Key Insights

About This Report

Report ID30234
Category Biotechnology
Published DateMay 2019
Updated DateSep 2020
Contact Us